



CENTER FOR MEDICARE

January 28, 2023

Corrective Action Plan

Contract ID: H3330

Parent Organization Name: EmblemHealth, Inc.

Legal Entity Name: HEALTH INSURANCE PLAN OF GREATER NEW YORK

Carly Borenkind
Medicare Compliance Officer
55 Water Street
New York, NY 10041

VIA EMAIL: cborenkind@emblemhealth.com

RE: Failure to Comply with CMS CY 2023 Bid Instructions

Dear Carly Borenkind:

The Centers for Medicare & Medicaid Services (CMS) is issuing a request for HEALTH INSURANCE PLAN OF GREATER NEW YORK, which operates Medicare Part D Contract ID H3330, to develop and implement a corrective action plan (CAP) to address the organization's failure to comply with contract year (CY) 2023 Part D bid submission requirements.

Part D program regulations at 42 C.F.R. § 423.265(c) state that each potential Part D sponsor must submit bids (and supplemental information specified by CMS) that reflect the features (e.g., premium amount, cost sharing) and projected cost estimates of each benefit package it expects to offer. For CY 2023, sponsors provided their bid information through three different submissions: a proposed formulary, a Bid Pricing Tool (BPT), and a Plan Benefit Package (PBP) submitted together by the statutory June 6, 2022 deadline. In general, the PBP describes the structure of a proposed benefit package (e.g., co-pay amounts, deductibles) while the BPT describes the underlying basis used to calculate the price of the benefit package. The information in all three of these submissions must combine to reflect a consistent benefit package. Additionally, pursuant to 42 C.F.R. § 423.505(k)(4), the sponsor's CEO or CFO must submit a certification (referred to as the "benefit certification") that the information provided in each bid is accurate, complete, and truthful.

Federal regulations at 42 C.F.R. § 423.104(f)(3) state that an MA organization offering coordinated care plans must offer required prescription drug coverage throughout its service area. The regulations at 42 C.F.R. § 423.100 define "required prescription drug coverage" as the coverage of Part D drugs under either a basic prescription drug plan or an enhanced alternative plan provided there is no MA monthly supplemental beneficiary premium applied under the plan.

Organizations are responsible for ensuring that complete and accurate CY 2023 bids were submitted by the June 6, 2022 deadline. Yet, the Part D portion of H3330's initial MA-PD bid failed to constitute

required prescription drug coverage in all of its service areas, resulting in your contract being deemed an outlier. The need for CMS to work with H3330 to correct its CY 2023 bid to ensure that it would offer required drug coverage as outlined in 42 C.F.R. § 423.104(f)(3) indicates that it failed to comply with Part D regulatory requirements and follow CMS bid instructions.

Consistent with CMS's authority under 42 C.F.R. § 423.505(n)(3)(iii), we request that your organization take corrective action to come into compliance. CMS will rely on H3330's CY 2024 bid submission to determine whether the corrective action plan has been successfully implemented. CMS will consider the CAP closed once the Division of Formulary and Benefit Operations has determined that H3330's CY 2024 bid submission demonstrates that it has effectively resolved the issues described above.

Please be aware that this letter will be included in the record of your organization's past Medicare contract performance, which CMS will consider as part of our review of any application for new or expanded Medicare contracts your organization may submit. CMS deems this instance of non-compliance a Part D issue. CMS notes that we are issuing this compliance notice based on information that we obtained from sources other than the sponsor's own self-disclosure.

For questions regarding your bid submission, please contact the Part D Benefits mailbox at PartDBenefits@cms.hhs.gov. If you have any questions about the compliance implications of this notice, please contact Christine Hill at Christine.Hill@cms.hhs.gov and copy your account manager.

Sincerely,



Amy Larrick Chavez-Valdez, Director

Medicare Drug Benefit and C&D Data Group

CC via email:

ALLAN AUGUSTE, JOAQUIN CLINTON-CLEMENS, CMS

Linda Anders, CMS

Arianne Spaccarelli, CMS

Christine Hill, CMS

